21世纪经济报道记者季媛媛 2026年的春天,核药赛道没有一丝“倒春寒”的迹象。 4月中旬,两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起:百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2(吉伦泰)正式获批,这是全球首个用于SPECT显像的广谱肿瘤显像剂,打破了PET技术近30年的垄断。 另一则是关于“中国实力”的彰显:远大医药宣布其钇[90Y]微球注射液在美国的...
Source Link21世纪经济报道记者季媛媛 2026年的春天,核药赛道没有一丝“倒春寒”的迹象。 4月中旬,两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起:百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2(吉伦泰)正式获批,这是全球首个用于SPECT显像的广谱肿瘤显像剂,打破了PET技术近30年的垄断。 另一则是关于“中国实力”的彰显:远大医药宣布其钇[90Y]微球注射液在美国的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.